Rhumbline Advisers Keros Therapeutics, Inc. Transaction History

Rhumbline Advisers

$121 Billion
Q3 2025

A detailed history of Rhumbline Advisers transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 50,478 shares of KROS stock, worth $871,250. This represents 0.0% of its overall portfolio holdings.

Number of Shares

50,478

Previous 51,815 2.58%

Holding current value

$871,250

Previous $691,000 15.48%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 06, 2025	SELL	$13.34 - $16.05 $17,835 - $21,458	-1,337 Reduced 2.58%	50,478 $798,000
Q2 2025 Aug 12, 2025	BUY	$9.55 - $15.11 $68,244 - $107,976	7,146 Added 16.0%	51,815 $691,000
Q1 2025 Apr 08, 2025	BUY	$10.15 - $16.1 $38,590 - $61,212	3,802 Added 9.3%	44,669 $481,000
Q4 2024 May 29, 2025	SELL	$15.64 - $70.0 $59,463 - $266,140	-3,802 Reduced 8.51%	40,867 $646,000
Q4 2024 Jan 30, 2025	BUY	$15.64 - $70.0 $6,115 - $27,370	391 Added 0.97%	40,867 $646,000

Q3 2024 Nov 12, 2024	SELL	$41.68 - $58.07 $48,432 - $67,477	-1,162 Reduced 2.79%	40,476 $2.35 Million
Q2 2024 Aug 01, 2024	BUY	$44.58 - $66.89 $317,008 - $475,654	7,111 Added 20.6%	41,638 $1.9 Million
Q1 2024 May 09, 2024	BUY	$41.26 - $70.48 $118,416 - $202,277	2,870 Added 9.07%	34,527 $2.29 Million
Q4 2023 Feb 08, 2024	SELL	$27.12 - $41.05 $24,028 - $36,370	-886 Reduced 2.72%	31,657 $1.26 Million
Q3 2023 Nov 09, 2023	SELL	$31.57 - $43.02 $12,943 - $17,638	-410 Reduced 1.24%	32,543 $1.04 Million
Q2 2023 Aug 08, 2023	BUY	$37.26 - $51.01 $181,158 - $248,010	4,862 Added 17.31%	32,953 $1.32 Million
Q1 2023 May 11, 2023	BUY	$41.44 - $59.32 $70,738 - $101,259	1,707 Added 6.47%	28,091 $1.2 Million
Q4 2022 Feb 14, 2023	BUY	$39.45 - $51.77 $119,415 - $156,707	3,027 Added 12.96%	26,384 $1.27 Million
Q3 2022 Nov 10, 2022	BUY	$27.8 - $40.12 $86,346 - $124,612	3,106 Added 15.34%	23,357 $879,000
Q2 2022 Aug 11, 2022	BUY	$26.03 - $67.04 $113,620 - $292,629	4,365 Added 27.48%	20,251 $560,000
Q1 2022 May 12, 2022	BUY	$42.12 - $59.36 $83,566 - $117,770	1,984 Added 14.27%	15,886 $864,000
Q4 2021 Feb 10, 2022	SELL	$36.95 - $62.89 $10,456 - $17,797	-283 Reduced 2.0%	13,902 $813,000
Q3 2021 Nov 12, 2021	BUY	$29.27 - $43.71 $19,903 - $29,722	680 Added 5.04%	14,185 $561,000
Q2 2021 Aug 05, 2021	SELL	$42.4 - $70.11 $7,208 - $11,918	-170 Reduced 1.24%	13,505 $574,000
Q1 2021 May 06, 2021	BUY	$54.0 - $75.28 $3,456 - $4,817	64 Added 0.47%	13,675 $842,000
Q4 2020 Feb 10, 2021	BUY	$36.0 - $82.74 $237,168 - $545,091	6,588 Added 93.81%	13,611 $960,000
Q3 2020 Nov 12, 2020	SELL	$27.04 - $62.21 $21,929 - $50,452	-811 Reduced 10.35%	7,023 $271,000
Q2 2020 Aug 13, 2020	BUY	$20.08 - $40.39 $157,306 - $316,415	7,834 New	7,834 $294,000

Others Institutions Holding KROS

# of Institutions

169

Shares Held

35.4M

Call Options Held

574K

Put Options Held

325K

View Full List

About Keros Therapeutics, Inc.

Ticker KROS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,757,000
Market Cap $445M
Description
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...

More about KROS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account

Rhumbline Advisers Keros Therapeutics, Inc. Transaction History